Literature DB >> 31815039

HSF1/AMPKα2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells.

Jia Hu Shen1, Ping Hua Chen2, He Deng Liu1,2, Dan Ai Huang2, Miao Miao Li1, Kun Guo1.   

Abstract

Recent studies suggest that up-regulated HSF1 possesses metabolic phenotypes switch and chemoresistance in cancer cells. However, the mechanism in which these characteristics are still ambiguous. Our study aims to identify how HSF1 confers chemoresistance through regulating metabolic pathway in hepatocellular carcinoma (HCC). Oxaliplatin (OXA)-resistant HCC cells (HCC-OXR) in both of abundant glucose (AG; 25 mM) and low glucose (LG; 5.5 mM) conditions were constructed; then glucose consumption, lactate production, intracellular ATP level and oxygen consumption of parental and OXA-resistant cells were determined by using the associated detected kits. Moreover, HSF1 was knocked down to analyze its effects on metabolic phenotypes alteration and chemoresistance formation in HCC cells. Compared to cells in AG condition, HCC cells delayed to form chemoresistance to OXA in LG condition; and OXA-resistant cells underwent a metabolic switch from glycolysis to oxidative phosphorylation (OXPHOS), which presented decreased glucose uptake and lactate production with increased levels of oxygen consumption and intercellular ATP; interestingly, this energy-producing pathway was blocked in HSF1-knockdown OXA-resistant cells, especially in LG condition. Analysis on previous data revealed that AMPK pathway was a critical regulator in the metabolism of OXA-resistance HCC cells. Furthermore, AMPKα2 was identified as an important factor regulated by HSF1 to achieve metabolic phenotype switch in OXA-resistance HCC cells. Consequently, these results suggest that combining restrictive glucose uptake and targeting HSF1/AMPKα2 is an attractive strategy to prevent chemoresistance to OXA in HCC patients. AJCR
Copyright © 2019.

Entities:  

Keywords:  AMPK; HSF1; Hepatocellular carcinoma; chemoresistance; glycolysis; oxaliplatin

Year:  2019        PMID: 31815039      PMCID: PMC6895450     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  5 in total

1.  LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.

Authors:  Ruyue Xu; Yinci Zhang; Amin Li; Yongfang Ma; Wenpeng Cai; Li Song; Yinghai Xie; Shuping Zhou; Weiya Cao; Xiaolong Tang
Journal:  Mol Med Rep       Date:  2021-05-13       Impact factor: 2.952

2.  Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma.

Authors:  Miaomiao Li; Juntao Hu; Riming Jin; Hongxia Cheng; Huaping Chen; Limin Li; Kun Guo
Journal:  J Hepatocell Carcinoma       Date:  2020-12-08

3.  Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2-mediated autophagy.

Authors:  Lang Fang; Jialun Lv; Zhe Xuan; Bowen Li; Zheng Li; Zhongyuan He; Fengyuan Li; Jianghao Xu; Sen Wang; Yiwen Xia; Tianlu Jiang; Lu Zhang; Linjun Wang; Diancai Zhang; Hao Xu; Li Yang; Zekuan Xu; Weizhi Wang
Journal:  Clin Transl Med       Date:  2022-01

4.  Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.

Authors:  Qingguo Li; Huizhen Sun; Dakui Luo; Lu Gan; Shaobo Mo; Weixing Dai; Lei Liang; Yufei Yang; Midie Xu; Jing Li; Peiyong Zheng; Xinxiang Li; Yan Li; Ziliang Wang
Journal:  J Exp Clin Cancer Res       Date:  2021-11-05

5.  UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.

Authors:  Zhan Shi; Runkun Liu; Qiliang Lu; Zhi Zeng; Yang Liu; Junjun Zhao; Xin Liu; Lijie Li; Hui Huang; Yingmin Yao; Dongsheng Huang; Qiuran Xu
Journal:  Int J Med Sci       Date:  2021-10-11       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.